{"contentid": 487934, "importid": NaN, "name": "$157 million financing round a \u00e2\u0080\u0098monumental moment\u00e2\u0080\u0099 for atai", "introduction": "CNS specialist atai Life Sciences has announced the successful closing of its $157 million Series D financing.", "content": "<p>CNS specialist atai Life Sciences has announced the successful closing of its $157 million Series D financing.</p>\n<p>The round was led by existing investors Apeiron Investment Group, the family office of atai&rsquo;s founder Christian Angermayer, Thiel Capital, and Woodline Partners LP.</p>\n<p>Other investors included Fearless Ventures, Falcon Edge Capital, Catalio Capital Management, Michael Auerbach&rsquo;s Subversive Capital and Highline Capital.</p>\n<p><span class=\"pullQuote\">\"The only company in neuropsychiatry today thoughtfully pursuing platform diversity alongside scientific depth\"</span>Proceeds from the financing will support the expansion and development of the Berlin-based company&rsquo;s pipeline and enabling technologies, and provide the necessary runway to continue advancing its current clinical developments.</p>\n<p>Florian Brand, chief executive and co-founder of atai, said: &ldquo;This marks a monumental moment for atai. We continue on our mission challenging the current way mental health conditions are treated. We have become better equipped than ever to accelerate the development of more efficacious treatments.&rdquo;</p>\n<p>Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai seeks to acquire, incubate and efficiently develop innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.</p>\n<p>Jason Camm, managing director and chief medical officer of Thiel Capital, said: &ldquo;We are excited to continue supporting atai, the only company in neuropsychiatry today that is thoughtfully pursuing platform diversity alongside scientific depth. The company is well-positioned to deliver on the vision of its founders by creating a new wave of therapies for patients in need.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-03-03 16:03:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 15:22:11", "updated": "2021-03-03 16:03:25", "access": NaN, "url": "https://www.thepharmaletter.com/article/157-million-financing-round-a-monumental-moment-for-atai", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "atai_life_sciences_large.png", "image2id": "atai_life_sciences_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Business Financing, Management, Research", "geography_tag": "Germany", "company_tag": "ATAI Life Sciences", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 16:03:00"}